Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is making strides in precision oncology by advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed for biomarker-selected cancers. The company is building the manufacturing and scientific groundwork necessary to move the program toward first-in-human studies, including polymer process development and analytical characterization with Nanosoft Polymers, as well as metabolism studies through Nucro-Technics as part of its IND-enabling program.
These efforts are aimed at supporting scalable manufacturing, characterizing ONC010’s metabolic profile, and generating data for future pharmacokinetic, toxicology, and regulatory activities. By integrating targeted PNKP inhibition, nanoparticle drug delivery, and AI-driven discovery capabilities, Onco-Innovations is positioning its platform to address cancers that may be particularly susceptible to DNA damage response approaches.
The significance of this development lies in the growing shift toward precision medicine in oncology. Biomarker-driven therapies allow for more personalized treatment, potentially improving efficacy and reducing side effects compared to traditional approaches. ONC010’s mechanism targets PNKP, an enzyme involved in DNA repair, which could make certain cancer cells more vulnerable to treatment. The nanoparticle encapsulation aims to enhance delivery and reduce toxicity, addressing common challenges in cancer therapy.
For patients, this could mean access to more targeted treatment options, especially for those with specific genetic markers. For the industry, it underscores the importance of investing in robust manufacturing and analytical processes early in drug development to ensure smooth transitions to clinical trials and eventual commercialization. The collaboration with Nanosoft Polymers and Nucro-Technics highlights the need for specialized expertise in nanomedicine and metabolic profiling.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue prevention and treatment through innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. More information is available at https://oncoinnovations.com/.
The latest news and updates regarding ONNVF can be found in the company’s newsroom at https://ibn.fm/ONNVF. As precision oncology continues to expand, Onco-Innovations is positioning itself at the forefront by building the foundation needed to advance ONC010 toward clinical application.
